Regulus Therapeutics Inc (RGLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has a cash flow conversion efficiency ratio of -0.154x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.61 Million) by net assets ($69.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Regulus Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Regulus Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Regulus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Regulus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regulus Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mirae Asset Venture Investment Co. Ltd
KQ:100790
|
-0.001x |
|
Mistras Group Inc
NYSE:MG
|
0.012x |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
0.032x |
|
Idaho Strategic Resources Inc
NYSE MKT:IDR
|
0.031x |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
-0.006x |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
N/A |
|
DBAPPSecurity Co Ltd
SHG:688023
|
0.004x |
|
AB S.A.
WAR:ABE
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Regulus Therapeutics Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Regulus Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.41 Million | $-41.67 Million | -0.545x | +56.83% |
| 2023-12-31 | $21.19 Million | $-26.77 Million | -1.263x | -64.77% |
| 2022-12-31 | $33.29 Million | $-25.53 Million | -0.767x | -74.65% |
| 2021-12-31 | $54.96 Million | $-24.13 Million | -0.439x | +8.85% |
| 2020-12-31 | $26.03 Million | $-12.54 Million | -0.482x | +51.36% |
| 2019-12-31 | $20.02 Million | $-19.82 Million | -0.990x | -113.40% |
| 2018-12-31 | $-5.85 Million | $-43.27 Million | 7.392x | +542.92% |
| 2017-12-31 | $35.22 Million | $-58.77 Million | -1.669x | -64.53% |
| 2016-12-31 | $56.08 Million | $-56.88 Million | -1.014x | -152.44% |
| 2015-12-31 | $124.08 Million | $-49.86 Million | -0.402x | -34.26% |
| 2014-12-31 | $132.01 Million | $-39.51 Million | -0.299x | +1.27% |
| 2013-12-31 | $93.46 Million | $-28.33 Million | -0.303x | -115.83% |
| 2012-12-31 | $62.09 Million | $-8.72 Million | -0.140x | -138.69% |
| 2011-12-31 | $-41.49 Million | $-15.06 Million | 0.363x | -76.41% |
| 2010-12-31 | $8.00 Million | $12.31 Million | 1.539x | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more